State Street Health Care Select Sector SPDR ETF (XLV)
| Assets | $43.42B |
| Expense Ratio | 0.08% |
| PE Ratio | 25.02 |
| Shares Out | 258.57M |
| Dividend (ttm) | $2.53 |
| Dividend Yield | 1.50% |
| Ex-Dividend Date | Jun 22, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 37.54% |
| Volume | 5,835,207 |
| Open | 168.44 |
| Previous Close | 167.77 |
| Day's Range | 167.76 - 169.10 |
| 52-Week Low | 133.73 |
| 52-Week High | 176.60 |
| Beta | 0.57 |
| Holdings | 63 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe State Street Health Care Select Sector SPDR ETF (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
60.62% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 14.87% |
| Johnson & Johnson | JNJ | 10.63% |
| AbbVie Inc. | ABBV | 7.66% |
| Merck & Co., Inc. | MRK | 5.91% |
| UnitedHealth Group Incorporated | UNH | 5.63% |
| Thermo Fisher Scientific Inc. | TMO | 3.98% |
| Amgen Inc. | AMGN | 3.36% |
| Gilead Sciences, Inc. | GILD | 3.03% |
| Abbott Laboratories | ABT | 2.95% |
| Pfizer Inc. | PFE | 2.59% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 22, 2026 | $0.65625 | Jun 24, 2026 |
| Mar 23, 2026 | $0.59468 | Mar 25, 2026 |
| Dec 22, 2025 | $0.65682 | Dec 24, 2025 |
| Sep 22, 2025 | $0.62487 | Sep 24, 2025 |
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
Performance
XLV had a total return of 25.44% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.71%.
News
Midterms Won't Settle Washington's Volatility
Political volatility should stay elevated even after Democrats retake the House this November, State Street Investment Management said. Republicans are still expected to hold the Senate, leaving littl...
Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets
With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets.
Blend Innovative Growth & Defense With Healthcare ETFs
All too often, when investors look at the healthcare sector, they mostly see its value for its defensive merits. However, that view may be shortsighted and miss the broader picture in today's market.
XLE, XLF & XLV Forecast: Energy Eyes Breakout as XLV Slips
XLE eyes fresh highs as oil rises, while XLF consolidates and XLV tests key support after breaking below a major trendline.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
XLV, XLK and MOO Forecast: Agriculture ETF Breaks Out
MOO has recently broken out and is showing real momentum, while XLV continues its uptrend and XLK holds around the 50-day EMA. The agriculture ETF carries the strongest bullish outlook of the three.
The Best High-Yield ETFs for Rising Interest Rates
Worries about slowing growth and inflation may benefit defensive funds focusing on sectors like utilities, consumer staples and healthcare.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
The Big 3: XLV, ARM, NKE
Don Kaufman (@Theotrade) sees two strong bearish opportunities and one "shot" to the upside on Wednesday's Big 3. He sees a likely pullback in the State Street Health Care Sector SPDR ETF (XLV) amidst...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Healthcare sector looks to be a beneficiary of the turbulence in tech: Renaissance Macro's deGraaf
Jeff deGraaf, Renaissance Macro chairman, joins 'Closing Bell' to discuss the technical indicators moving equity markets, the healthcare sector and much more.
Healthcare Investing Is Now an AI Short in Disguise
Big healthcare companies are increasingly trading opposite to tech.
Sector ETFs Post Record $25B Inflow as Tech Leads
U.S.-listed sector ETFs pulled in a record $25 billion in July, according to a report from State Street Investment Management. Investors used a sharp technology selloff to load up on artificial intell...
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulatio...
Showstopper Healthcare Earnings Elevate Use Case for XLV
Wednesday, August 5th may have felt like an average Summer day, but it actually represented a compelling inflection point for the healthcare industry. This is because a few key healthcare giants repor...
How ETF investors should view the ‘great expectations' of earnings season
Is the old adage ‘be careful what you wish for' coming into play on Wall Street during earnings season? JPMorgan Asset Management chief ETF strategist Jon Maier and VettaFi director of research Cinthi...
Risk-Wary Family Offices Double Down on Infrastructure
Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.
As semiconductor stocks slump, one AI-adjacent sector is thriving — and these are the stocks to buy
Another way to exploit the AI evolution is available for investors
Why Healthcare Stocks Look Like a Haven in This Market
Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.
3 Healthcare ETFs to Own in a Choppy Stock Market
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
Healthcare trade offers demand characteristics not tied to AI: Wealth Enhancement's Yoshioka
CNBC's “Closing Bell Overtime” team discusses whether recent momentum can last in the healthcare trade and how investors can diversify with Ayako Yoshioka, senior investment strategist at Wealth Enhan...
Market rotation is the most prevalent factor for healthcare outperformance, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
No tech, no problem. Dow makes record and traders think these stocks can lead now
Traders bought about 5,300 calls in the State Street Health Care Select Sector SPDR ETF (XLV) on Thursday, compared to just over 1,000 puts, according to data from ThinkOrSwim.
The Big 3: XLV, BA, SAP
Traders "live for days like these," says @Theotrade's Don Kaufman in referencing Wednesday's volatility. He offers a trio of example options trades he sees as opportunities in the price action.
The Stocks Goldman Sachs Thinks You Should Own as Iran War Stretches Into a Third Week
The war in Iran is entering its third week with no end in sight. That, according to Goldman Sachs analysts, warrants some portfolio changes.
Health care and industrials are the sectors to put money to work: Crossmark's Victoria Fernandez
Victoria Fernandez, Crossmark Global Investments, joins 'Closing Bell' to discuss the recent price action in oil, the strength in tech stocks and more.
Time for Investors to Get Defensive. Sell Staples and Buy Healthcare.
The market is shaky, software stocks have gone off a cliff, and semiconductor stocks are giving back some of their gain. It's time to tweak your portfolio.
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Josh Brown's ‘best stocks in the market': Health Care
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he's spotlighting Health Care in his "best stocks in the market." The Committee debates their health care s...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Momentum and private assets: The trends driving ETFs to record inflows
ETF inflows are already at record annual flows. Todd Rosenbluth, VettaFi head of research, on what's driving the momentum and the trends that are standing out.
Schwab IMPACT 2025: Record $13T in ETFs & What's Next for ETF Assets
Matt Camuso, Head of ETF Solutions at BNY Investments, says there are $13 trillion of assets in ETFs. That's compared to $5 trillion a year prior.
State Street's Anna Paglia on why the firm is shifting from ETFs to mutual funds
Anna Paglia, State Street Investment Research CBO and chief business officer, joins CNBC's Dom Chu on the type of assets and ETFs State Street is seeing the flows into. She also shares why the firm is...